Company
Cyteir Therapeutics
Cancer’s Vulnerability is Our Strength
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Headquarters
- Lexington, Massachusetts, United States
Claim, correct or request removal
Record updated 28 September 2026
About
Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
Funding snapshot
- Total raised
- $112MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $80M2021-02-05
Funding rounds
- Round, 2021
- $80M2021-02-05, SEC form D sold, 22 investors
- Round, 2019
- $20.2M2019-09-27, SEC form D sold, 6 investors
- Round, 2018
- $5.8M2018-01-03, SEC form D sold, 12 investors
- Round, 2015
- $5.8M2015-10-27, SEC form D sold, 15 investors
Products
- Other
- CYT-0851
Loading relationship preview